Obtaining a Natural Product Number (NPN) is an important milestone for companies marketing Natural Health Products (NHPs) in Canada, but regulatory compliance does not end when a product licence is issued. Manufacturers, importers, and product licence holders must continue to maintain product quality, appropriate specifications, Good Manufacturing Practices (GMP), and supporting documentation throughout a product’s commercial lifecycle.
Health Canada’s proposed 2026 Quality of Natural Health Products Guide reinforces this ongoing responsibility by introducing more detailed guidance on Finished Product Specifications (FPS), analytical testing, stability, supplier-related changes, and post-licensing quality management. Together with the updated GMP Guide (GUI-0158, Version 4), implemented in March 2026, the proposed revisions reflect a more integrated approach to NHP quality oversight.
Although the revised Quality Guide remains in draft form, companies can begin evaluating their existing quality systems, identifying documentation gaps, reviewing importation arrangements, and ensuring personnel understand their GMP responsibilities. Preparing early may help reduce compliance challenges when the guidance is finalized and implemented.
For companies developing Natural Health Products for the Canadian market, obtaining a product licence is often the primary regulatory objective. Once Health Canada authorizes the product and issues an NPN, attention typically shifts toward manufacturing, importing, distribution, and commercial sales.
However, an NPN confirms that a product has received market authorization. It does not eliminate the ongoing responsibilities associated with maintaining its quality.
Under the Natural Health Products Regulations, product licence holders are responsible for maintaining appropriate product specifications and ensuring their products continue to meet applicable regulatory requirements. Manufacturers, importers, packagers, labellers, and distributors must also comply with the GMP requirements relevant to their activities.
These responsibilities continue after the initial product licence is issued.
For example, a Canadian company may obtain an NPN for a botanical supplement manufactured overseas. Although the formulation remains unchanged, the foreign manufacturer may subsequently change its raw material supplier, analytical testing method, or manufacturing process.
Such changes may affect the finished product’s identity, composition, purity, or stability. The company must evaluate whether its existing specifications and supporting quality documentation remain appropriate and whether any regulatory action is required.
Health Canada’s proposed Quality Guide places greater emphasis on managing these situations throughout the product lifecycle rather than treating quality primarily as a component of the initial licensing process.
Health Canada has been modernizing its NHP quality guidance to reflect advances in manufacturing practices, analytical science, and regulatory oversight.
Two important developments illustrate this direction.
The first was the publication of the updated Good Manufacturing Practices Guide for Natural Health Products (GUI-0158, Version 4) in September 2025, which was implemented on March 4, 2026.
The updated GMP Guide provides more detailed guidance on quality systems, quality risk management, documentation, personnel responsibilities, supplier oversight, investigations, and product release.
The second development is Health Canada’s proposed revision of the Quality of Natural Health Products Guide, released for consultation in July 2026.
The proposed guide expands the scientific and operational guidance used to establish and maintain product quality, including analytical methods, product specifications, performance testing, stability, and post-licensing changes.
Together, these documents describe complementary aspects of NHP quality management:
This does not mean Health Canada is introducing an entirely new legal requirement to maintain product quality. The Natural Health Products Regulations already require products available for sale to comply with their specifications and assign ongoing GMP responsibilities according to the activities each company performs. The current 2015 Quality Guide explains how to meet applicable product quality requirements.
Rather, the proposed revisions provide substantially more detailed recommendations on how those responsibilities should be supported through scientific evidence, documentation, and operational quality controls.
For companies already operating in Canada, the practical question is whether their existing quality management practices are sufficiently developed to meet these evolving expectations.
Lifecycle quality management involves maintaining appropriate controls over a product from its initial development and licensing through manufacturing, importation, distribution, and post-market activities.
The proposed Quality Guide addresses several areas where companies may need to strengthen their existing processes.
Maintaining Finished Product Specifications
Finished Product Specifications (FPS) establish the quality standards a product must meet, including requirements related to medicinal ingredient identity, quantity, purity, and potency, where applicable.
Under the current regulatory framework, specifications must be established and maintained. The proposed Quality Guide places greater emphasis on using FPS as operational quality documents that support manufacturing, product release, stability testing, and post-licensing maintenance.
If a company switches to an updated pharmacopoeial method, it should assess the method’s suitability, document the change and determine whether a product licence amendment is required. Under paragraph 11(1)(i) of the Natural Health Products Regulations, the licence must be amended before affected lots can be sold if the change removes a method listed in the specifications, widens the applicable tolerances through a method modification, or makes the method less precise, accurate, specific or sensitive.The proposed guidance also provides more detailed recommendations concerning analytical method validation, verification, equivalency, and method transfer.
Companies should therefore consider whether their existing FPS accurately reflect the products being manufactured and the methods currently used to evaluate them.
Managing Supplier and Manufacturing Changes
Changes to suppliers, raw materials, manufacturing processes, or testing laboratories can introduce new quality considerations, even when the product’s labelled ingredients remain unchanged.
For example, an NHP manufacturer may switch to a new supplier of a botanical extract that meets the same declared ingredient quantity but uses a different extraction process.
Differences in extraction conditions may affect the composition of the material, including the concentration of certain constituents or impurities.
The manufacturer and other responsible parties should evaluate whether existing identity tests, specifications, and safety-related quality controls remain suitable for the new material.
Depending on the nature of the change, additional testing, documentation, or a product licence amendment or notification may be necessary.
The proposed Quality Guide reinforces the importance of connecting these operational changes with the scientific information used to establish product quality.
Maintaining Stability Throughout the Product Lifecycle
Stability testing helps establish whether an NHP will continue to meet its specifications throughout its assigned shelf life under the recommended storage conditions.
Health Canada’s existing GMP requirements already address stability. However, the proposed Quality Guide provides more detailed recommendations concerning packaging configurations, transportation, storage conditions, and in-use stability.
For example, a company may initially market an NHP in a sealed bottle and later introduce a blister-pack presentation.
Although the formulation has not changed, the packaging materials may provide different levels of protection against moisture, oxygen, or other environmental factors.
The draft Quality Guide recommends separate stability studies for each packaging presentation, such as bottles and blister packs. The current GMP Guide also recognizes that bracketing or matrixing may reduce the number of studies needed for products sold in multiple package types. Companies should assess whether their existing data support the proposed packaging and document the scientific basis for their study design. Companies planning packaging changes or introducing new product formats should evaluate whether their existing stability evidence remains representative of the product being marketed.
Strengthening Analytical Testing and Quality Documentation
The proposed Quality Guide also expands recommendations for analytical testing, including method suitability, documentation, and the scientific justification supporting particular testing approaches.
This may be especially relevant for companies relying on contract laboratories, alternative analytical methods, or quantification by input for complex botanical formulations.
For example, an NHP company may rely on a third-party laboratory to conduct finished-product testing. If the laboratory changes its analytical procedure, the company should evaluate whether the revised method is appropriate for the product and whether supporting verification or equivalency information is necessary.
Maintaining current documentation is essential because quality decisions depend on reliable evidence demonstrating that the product continues to meet applicable requirements.
Importers have an important role in Canada’s NHP quality framework because products manufactured outside Canada must still meet applicable Canadian requirements before they are released for sale.
A foreign manufacturer’s compliance with its domestic regulatory requirements does not automatically establish compliance with Canada’s Natural Health Products Regulations.
Under Health Canada’s current GMP Guide, importers are subject to applicable requirements concerning specifications, quality assurance, stability, records, and product release.
The proposed Quality Guide reinforces the importance of confirming that imported products meet their established specifications and that the supporting scientific and quality documentation remains appropriate.
For example, a Canadian importer may receive finished NHPs from an overseas contract manufacturer. The manufacturer provides Certificates of Analysis (CoAs), batch documentation, and supporting test results.
The importer must have appropriate procedures to evaluate this information and ensure that the products meet Canadian requirements before release.
If the manufacturer changes its testing laboratory, raw material source, or production process, the importer may need additional information to determine whether the existing quality documentation remains sufficient.
This creates an ongoing need for communication and quality oversight between the Canadian importer and its foreign manufacturing partners.
Companies importing NHPs into Canada may encounter several operational challenges:
These activities can require specialized regulatory and quality assurance expertise, particularly for companies with limited Canadian operations.
For businesses entering the Canadian market, establishing an independent licensed importation operation may involve developing the necessary quality systems, procedures, personnel arrangements, and documentation controls.
An alternative is to work with an established Canadian NHP importer that already maintains the appropriate licensed infrastructure and quality assurance systems.
Although Health Canada’s revised Quality Guide remains in draft form, the proposed recommendations provide a useful framework for evaluating existing quality management practices.
The public consultation closed on September 20, 2026. Health Canada has indicated that it intends to publish a final version following its review of stakeholder feedback, with an appropriate transition and implementation period.
The final recommendations may differ from the consultation draft. Companies should therefore distinguish existing regulatory obligations from proposed guidance when developing their preparation strategies.
Several activities can help organizations identify potential compliance gaps before the revised guidance is implemented.
| Preparation Area | Recommended Action | Why It Matters |
| Finished Product Specifications | Review existing FPS against current products, methods, and applicable quality standards. | Helps identify outdated or insufficient specifications. |
| Analytical testing | Evaluate laboratory methods, supporting validation or verification records, and testing arrangements. | Supports scientifically defensible quality decisions. |
| Supplier oversight | Review supplier qualifications, quality agreements, and change-notification procedures. | Helps identify changes that could affect product quality. |
| Stability programs | Assess whether stability evidence supports current formulations, packaging, and storage conditions. | Helps demonstrate continued compliance throughout shelf life. |
| Importation controls | Review foreign manufacturer documentation, import verification procedures, and product-release arrangements. | Supports compliance with Canadian importation and GMP requirements. |
| Quality documentation | Evaluate SOPs, change control, deviation investigations, and recordkeeping procedures. | Helps maintain consistent and traceable quality oversight. |
| Personnel training | Review whether employees understand the GMP requirements relevant to their activities. | Supports consistent implementation of quality procedures. |
These activities do not necessarily require companies to redesign their entire quality management systems.
For some organizations, preparation may involve updating existing procedures or improving documentation. Others may identify more significant gaps requiring additional technical expertise, revised testing strategies, or changes to their operational arrangements.
A risk-based assessment can help determine which activities should receive priority.
Effective quality management depends not only on written procedures but also on the personnel responsible for implementing them.
Health Canada’s updated GMP Guide places considerable emphasis on qualified personnel, clearly defined responsibilities, appropriate documentation, and effective quality assurance oversight.
Employees involved in manufacturing, importing, testing, storage, distribution, and product release need to understand the requirements applicable to their activities.
For example, an employee responsible for receiving imported NHP shipments should understand the organization’s procedures for documentation review, product quarantine, escalation of discrepancies, and release authorization.
Similarly, personnel responsible for supplier management should understand how manufacturing or material changes are communicated, documented, and evaluated.
Training is particularly important when regulatory guidance changes because existing procedures may need to be updated and employees may require instruction on revised expectations.
While the proposed Quality Guide has not yet been finalized, companies can strengthen their readiness by ensuring personnel are appropriately trained on the GMP requirements already in effect.
dicentra offers Natural Health Product GMP Online Training designed to help manufacturers, importers, distributors, and quality assurance personnel understand Canadian GMP requirements.
The training reflects Health Canada’s updated GUI-0158, Version 4, and provides a practical foundation for understanding quality systems, personnel responsibilities, documentation, and other GMP principles.
For organizations reviewing their quality management practices in anticipation of the revised Quality Guide, training can be an important component of broader compliance preparation.
Explore dicentra’s NHP GMP Online Training
Maintaining NHP quality throughout the product lifecycle requires coordination between regulatory affairs, quality assurance, manufacturing, testing laboratories, and supply chain partners.
As Health Canada’s guidance evolves, companies may need to reassess whether their existing quality systems and operational arrangements provide sufficient oversight.
dicentra supports NHP companies through regulatory consulting, quality systems compliance, GMP assessments, and Canadian importation services.
For companies that manufacture NHPs outside Canada, establishing an independent licensed importation operation may not be the most practical approach.
dicentra’s Natural Health Product Importation Services allow eligible products to be imported under dicentra’s established Canadian Site Licence, with associated regulatory and quality assurance support.
This provides an alternative for companies seeking Canadian market access without independently developing and maintaining the infrastructure required for a licensed importation operation.
By working with an established Canadian importer, companies can access specialized support for applicable importation controls, quality documentation, and product-release requirements.
Learn More About dicentra’s NHP Importation Services
For companies maintaining their own manufacturing or importation operations, dicentra also provides consulting support for GMP compliance and quality systems.
Depending on the organization’s needs, this may include reviewing quality documentation, identifying gaps in existing procedures, evaluating supplier oversight arrangements, and preparing for regulatory inspections.
These services can help organizations assess their readiness for evolving Health Canada expectations while maintaining compliance with requirements already in effect.
Health Canada’s proposed Quality Guide reflects a broader direction in NHP regulation: product quality must be scientifically supported, consistently verified, and maintained throughout the product lifecycle.
While ongoing quality responsibilities are not new, the proposed guidance provides more detailed recommendations for connecting product specifications, analytical testing, stability, manufacturing, importation, and post-market maintenance.
For manufacturers and importers, this creates an opportunity to review existing quality systems before the revised guidance is finalized.
Companies that proactively assess their documentation, supplier relationships, testing arrangements, and personnel training may be better positioned to adapt to future expectations while reducing the risk of avoidable compliance issues.
Whether your organization is preparing to enter the Canadian market or strengthening an existing NHP quality program, dicentra can help you evaluate your regulatory and operational requirements.
Contact dicentra to discuss your NHP quality management, GMP compliance, or Canadian importation needs.